Veracyte and Yale Announce Exclusive License to Advance First Genomic Monitoring Test for Idiopathic Pulmonary Fibrosis

Author's Avatar
Apr 23, 2020
Article's Main Image

Veracyte%2C+Inc. (Nasdaq: VCYT) and Yale+University today announced an exclusive licensing agreement to advance the first genomic test for predicting disease progression in patients with idiopathic pulmonary fibrosis (IPF). The agreement gives Veracyte rights to a 52-gene signature developed by Yale researchers, for use on the nCounter FLEX Analysis System – Veracyte’s exclusively licensed diagnostics platform. Veracyte plans to make the non-invasive, blood-based test available as a complement to its Envisia Genomic Classifier, as part of a comprehensive offering to aid in the diagnosis and treatment of patients with IPF.